GRAIL (NASDAQ:GRAL) CFO Sells 3,000 Shares of Stock

GRAIL, Inc. (NASDAQ:GRAL – Get Free Report) CFO Aaron Freidin sold 3,000 shares of the firm’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $107.62, for a total transaction of $322,860.00. Following the completion of the sale, the chief financial officer directly owned 222,364 shares in the company, valued at approximately $23,930,813.68. This trade represents a 1.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aaron Freidin also recently made the following trade(s):

  • On Monday, October 5th, Aaron Freidin sold 23,619 shares of GRAIL stock. The shares were sold at an average price of $146.39, for a total transaction of $3,457,585.41.
  • On Monday, September 21st, Aaron Freidin sold 4,100 shares of GRAIL stock. The shares were sold at an average price of $93.34, for a total transaction of $382,694.00.
  • On Thursday, August 27th, Aaron Freidin sold 7,900 shares of GRAIL stock. The shares were sold at an average price of $85.01, for a total transaction of $671,579.00.

GRAIL Stock Performance

Shares of NASDAQ:GRAL traded down $10.29 during midday trading on Monday, hitting $105.60. 792,617 shares of the stock traded hands, compared to its average volume of 936,290. The business’s 50 day moving average is $121.96 and its two-hundred day moving average is $79.74. GRAIL, Inc. has a one year low of $41.50 and a one year high of $166.48.

GRAIL (NASDAQ:GRAL – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported ($2.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.45) by $0.24. GRAIL had a negative return on equity of 16.13% and a negative net margin of 243.80%. The company had revenue of $37.53 million for the quarter, compared to analysts’ expectations of $44.21 million. As a group, equities analysts anticipate that GRAIL, Inc. will post -9.11 EPS for the current year.

Hedge Funds Weigh In On GRAIL

Several hedge funds and other institutional investors have recently modified their holdings of GRAL. North Star Investment Management Corp. lifted its holdings in GRAIL by 809.1% in the third quarter. North Star Investment Management Corp. now owns 300 shares of the company’s stock worth $42,000 after buying an additional 267 shares during the period. Root Financial Partners LLC purchased a new position in shares of GRAIL during the 3rd quarter worth approximately $44,000. SBI Securities Co. Ltd. grew its holdings in shares of GRAIL by 110.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 388 shares of the company’s stock worth $54,000 after acquiring an additional 204 shares during the period. Fifth Third Bancorp raised its position in shares of GRAIL by 15,733.3% in the 1st quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock worth $25,000 after acquiring an additional 472 shares in the last quarter. Finally, Allworth Financial LP bought a new position in shares of GRAIL in the 2nd quarter worth approximately $35,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Royal Bank Of Canada increased their price objective on GRAIL from $84.00 to $100.00 and gave the stock a “sector perform” rating in a report on Thursday, November 5th. Piper Sandler boosted their target price on GRAIL from $74.00 to $130.00 and gave the company a “neutral” rating in a research note on Tuesday, November 10th. Robert W. Baird upped their target price on GRAIL from $96.00 to $118.00 and gave the company an “outperform” rating in a report on Tuesday, September 22nd. Wall Street Zen raised GRAIL from a “sell” rating to a “hold” rating in a research note on Sunday, September 13th. Finally, Mizuho lifted their price target on shares of GRAIL from $65.00 to $100.00 and gave the company a “neutral” rating in a report on Friday, September 25th. Five analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $128.80.

Check Out Our Latest Research Report on GRAL

About GRAIL

(Get Free Report)

GRAIL, Inc. is a healthcare company developing blood-based tests for the early detection of multiple cancers. Its approach analyzes patterns in cell-free DNA, including DNA methylation signals, to help identify a possible cancer signal and predict its origin in the body. GRAIL’s flagship product is Galleri, a multi-cancer early detection test intended for use alongside—not as a replacement for—recommended cancer screening. The company also conducts clinical research to evaluate the test and advance its early-detection technology.

Recommended Stories

Insider Buying and Selling by Quarter for GRAIL (NASDAQ:GRAL)

Receive News & Ratings for GRAIL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRAIL and related companies with MarketBeat.com's FREE daily email newsletter.